Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Exclusion Criteria

• •1. Participants with active central nervous system (CNS) metastases or carcinomatous meningitis
• •2. Participants with any serious or uncontrolled medical disorder or active infection with the hepatitis virus or the human immunodeficiency virus (HIV)
• •3. Participants with Grade 1 (NCI-CTCAE v.4.03) toxicities attributed to prior anti-cancer therapy (other than alopecia and fatigue) prior to randomization
• •4. Participants that have received nivolumab
• •5. Participants that have received therapy with anti-tumor vaccines or other immuno-stimulatory antitumor agents
• •6. Participants with a history of severe hypersensitivity reactions to monoclonal antibodies
• •7. Participants that have received therapy with anti-PD-1, anti-PD-L1, anti-PD-L-2, anti-CD-137, and/or anti CTLA-4 antibodies
• •8. Participants receiving any investigational agent within 28 days of first administration of trial treatment
• •9. Pregnant or lactating women